M. Holtkamp

604 total citations
13 papers, 442 citations indexed

About

M. Holtkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Holtkamp has authored 13 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in M. Holtkamp's work include Cancer Treatment and Pharmacology (4 papers), BRCA gene mutations in cancer (2 papers) and Neutropenia and Cancer Infections (2 papers). M. Holtkamp is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), BRCA gene mutations in cancer (2 papers) and Neutropenia and Cancer Infections (2 papers). M. Holtkamp collaborates with scholars based in Netherlands. M. Holtkamp's co-authors include Sjoerd Rodenhuis, Jan H. Schornagel, Jos H. Beijnen, Alwin D. R. Huitema, I. C. M. Slaper-Cortenbach, Elsken van der Wall, W J Nooijen, Joke W. Baars, Jolanda Schrama and Matthijs M. Tibben and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

M. Holtkamp

13 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Holtkamp Netherlands	9	220	128	99	98	81	13	442
V. Barbounis Greece	15	231 1.1×	102 0.8×	38 0.4×	71 0.7×	85 1.0×	31	481
Fabrizio Ganzina Italy	13	360 1.6×	141 1.1×	156 1.6×	62 0.6×	47 0.6×	23	601
Nitya Nathwani United States	12	186 0.8×	263 2.1×	198 2.0×	49 0.5×	39 0.5×	37	528
Paraskevi Roussou Greece	13	138 0.6×	100 0.8×	83 0.8×	120 1.2×	28 0.3×	21	528
Wilhelm Wößmann Germany	11	101 0.5×	276 2.2×	127 1.3×	69 0.7×	67 0.8×	23	544
C. Sessa Switzerland	10	203 0.9×	122 1.0×	38 0.4×	31 0.3×	39 0.5×	26	447
C Gilbert United States	10	372 1.7×	85 0.7×	398 4.0×	32 0.3×	60 0.7×	12	687
Christina L. Gersch United States	12	263 1.2×	136 1.1×	46 0.5×	24 0.2×	100 1.2×	30	472
P R Taylor United Kingdom	11	137 0.6×	158 1.2×	323 3.3×	48 0.5×	27 0.3×	20	517
Nishant Tageja United States	15	163 0.7×	188 1.5×	212 2.1×	76 0.8×	38 0.5×	33	516

Countries citing papers authored by M. Holtkamp

Since Specialization

Citations

This map shows the geographic impact of M. Holtkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Holtkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Holtkamp more than expected).

Fields of papers citing papers by M. Holtkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Holtkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Holtkamp. The network helps show where M. Holtkamp may publish in the future.

Co-authorship network of co-authors of M. Holtkamp

This figure shows the co-authorship network connecting the top 25 collaborators of M. Holtkamp. A scholar is included among the top collaborators of M. Holtkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Holtkamp. M. Holtkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Steenbruggen, Tessa G., Astrid N. Scholten, Ingrid A.M. Mandjes, et al.. (2017). Selecting patients with oligo-metastatic breast cancer harboring homologous recombination deficiency (HRD) for intensified chemotherapy: The OLIGO-study. Annals of Oncology. 28. v104–v104. 1 indexed citations

Sonke, Gabe S., Ingrid A.M. Mandjes, M. Holtkamp, et al.. (2013). Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer. The Breast Journal. 19(4). 419–426. 11 indexed citations

Vollebergh, Marieke A., Esther H. Lips, Petra M. Nederlof, et al.. (2010). An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology. 22(7). 1561–1570. 126 indexed citations

Maaskant, Jolanda, Jan Paul de Boer, Otilia Dalesio, M. Holtkamp, & Cees Lucas. (2009). The effectiveness of chlorhexidine-silver sulfadiazine impregnated central venous catheters in patients receiving high-dose chemotherapy followed by peripheral stem cell transplantation. European Journal of Cancer Care. 18(5). 477–482. 11 indexed citations

Schmidt, Marjanka K., Femke E. Froklage, M. Holtkamp, et al.. (2009). Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization.. Cancer Research. 69(2_Supplement). 6050–6050. 8 indexed citations

Jonge, Milly E. de, et al.. (2005). Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemotherapy and Pharmacology. 56(4). 370–378. 52 indexed citations

Schrama, Jolanda, M. Holtkamp, Joke W. Baars, Jan H. Schornagel, & Sjoerd Rodenhuis. (2003). Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. British Journal of Cancer. 88(12). 1831–1838. 20 indexed citations

Huitema, Alwin D. R., Manon C.W. Spaander, Ron A. A. Mathôt, et al.. (2002). Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Annals of Oncology. 13(3). 374–384. 51 indexed citations

Huitema, Alwin D. R., M. Holtkamp, Matthijs M. Tibben, Sjoerd Rodenhuis, & Jos H. Beijnen. (1999). Sampling Technique From Central Venous Catheters Proves Critical for Pharmacokinetic Studies. Therapeutic Drug Monitoring. 21(1). 102–104. 12 indexed citations

10.

Baars, Joke W., W.J. Nooyen, M. Holtkamp, et al.. (1997). Adjustment of the interface detector (location 71) to the absolute number of mononuclear cells in the peripheral blood: No improvement of the collection efficiency of the Fenwal CS3000 plus during progenitor cell harvests. Journal of Clinical Apheresis. 12(2). 68–73. 5 indexed citations

11.

Rodenhuis, Sjoerd, Anneke M. Westermann, M. Holtkamp, et al.. (1996). Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.. Journal of Clinical Oncology. 14(5). 1473–1483. 81 indexed citations

12.

Baars, Joke W., M. Holtkamp, W.J. Nooyen, et al.. (1996). Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.. PubMed. 16(5B). 3089–95. 8 indexed citations

13.

Wall, Elsken van der, Dick J. Richel, M. Holtkamp, et al.. (1994). Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size. Annals of Oncology. 5(9). 795–802. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact